Issue 42: February 23, 2022

TRENDING IN TRIALS

Essential Information for Principal Investigators at UAB

LATEST UPDATES



Cohort Feasibility and Recruitment Strategy often begins with i2b2, which was designed primarily for cohort identification, allowing users to perform an enterprise-wide search on a de-identified repository of health information to determine the existence of a set of patients meeting certain inclusion or exclusion criteria.

Learn more.



Facilities & Support You Need: The CCTS can connect you to specialized capacities and expertise, like <u>extended stays for healthy research participants</u> and <u>nutrition-related research support</u>. **Contact the CCTS to learn more.**

Center Stage at the Trial Innovation Network. Don't miss important learning opportunities related to inclusive study designs, site assessment tools and workforce development. Learn more about TIN Events.

Trial Triumph! Congratulations to Dr. Julie Kanter and team, who recently demonstrated initial findings of efficacy of a novel gene therapy in the treatment of vaso-occlusive events in sickle cell disease. Read more in the <u>February issue of NEJM</u>.

Thank you for reading, UAB Clinical Trials Administration Committee (CTAC)

Do you have news or updates to share with the clinical trials community at UAB? Send us an email!



